Contineum Therapeutics' (CTNM) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has **reiterated a sell (D-) rating** for Contineum Therapeutics (CTNM), reflecting concerns about the company's financial performance.
• Despite the negative rating from Weiss, **Morgan Stanley raised its target price** for CTNM shares from $20.00 to $21.00, indicating some investor confidence with an "overweight" rating.
• Contineum Therapeutics reported a quarterly loss of **($0.62) EPS**, missing analysts' estimates, as the company continues to develop therapies for significant unmet medical needs.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by research analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Several other research firms have also issued reports on CTNM. Morgan Stanley boosted their target price on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Monday, August 18th. Leerink Partners initiated coverage on Contineum Therapeutics in a research report on Thursday, September 25th. They issued an "outperform" rating and a $20.00 price objective for the company. Finally, Leerink Partnrs raised Contineum Therapeutics to a "strong-buy" rating in a research note on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Contineum Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.20.

Contineum Therapeutics Trading Down 0.6%

CTNM stock traded down $0.07 during trading on Friday, hitting $11.05. The company had a trading volume of 50,838 shares, compared to its average volume of 105,563. The stock has a market cap of $309.84 million, a PE ratio of -5.02 and a beta of 1.29. The business has a 50-day moving average of $11.20 and a 200-day moving average of $6.85. Contineum Therapeutics has a one year low of $3.35 and a one year high of $20.24.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). Research analysts forecast that Contineum Therapeutics will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in Contineum Therapeutics in the first quarter valued at approximately $93,000. ADAR1 Capital Management LLC raised its position in shares of Contineum Therapeutics by 105.2% during the first quarter. ADAR1 Capital Management LLC now owns 168,765 shares of the company's stock worth $1,178,000 after purchasing an additional 86,531 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Contineum Therapeutics in the 1st quarter worth $118,000. Strs Ohio acquired a new stake in Contineum Therapeutics in the 1st quarter valued at $27,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Contineum Therapeutics in the 2nd quarter valued at $140,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.